Bacci G, Briccoli A, Ferrari S, Saeter G, Donati D, Longhi A, Manfrini M, Bertoni F, Rimondini S, Monti C, Forni C
Sezione di Chemioterapia, Istituto Ortopedico Rizzoli, I-40136 Bologna, Italy.
Oncol Rep. 2000 Mar-Apr;7(2):339-46. doi: 10.3892/or.7.2.339.
We report on the clinical course and outcome of 28 patients, treated at The Istituti Ortopedici Rizzoli between 1995 and 1997 for osteosarcoma of the extremities metastatic to the lung at presentation. The treatment for these patients was the following: primary chemotherapy with cisplatin, adriamycin and high dose of methotrexate and ifosfamide followed by simultaneous resection of primary and metastatic lesions (when feasible), and further chemotherapy. After primary chemotherapy, lung metastases disappeared in 6 patients, whereas metastases in 3 remained surgically unresectable. These 9 patients received surgical treatment of the primary tumor only. In the remaining 19 patients, after chemotherapy, a simultaneous resection of the primary and metastatic tumor was performed. The resection of metastatic lesions was complete in 18 cases and incomplete in one. Three of the 4 patients who did not achieve a tumor-free status died in a few months and one is still alive with uncontrolled disease. With a median follow-up of 32 months (19-43) of the 24 patients who achieved remission, 12 (55%) remained continuously free of disease, 11 relapsed with new metastases and 1 died of chemotherapy-related toxicity. The 2-year DFS and OS were 36% and 53% respectively. These results are much worse than those achieved in 114 contemporary patients with localised disease (2-year DFS: 81%) treated in the same period and they are superimposible to the results achieved in 23 patients previously treated with the same protocol, but with standard dose of ifosfamide (2-year DFS: 32%). However, it must be underlined that, as regards prognosis, patients with metastatic disease at presentation are a hetero-geneous group. The DFS was significantly higher for patients with only one or two metastatic lesions than for patients with 3 or more lesions (2 year DFS: 78% vs. 28%). In 12 of the 19 patients who had a complete simultaneous resection of the primary and metastatic tumor, a strong correlation between the degree of necrosis of the primary and metastatic lesions was found. We conclude that in patients with osteosarcoma of the extremity with lung metastases at presentation: a) the combination of aggressive chemotherapy with simultaneous resection of primary and metastatic tumors works very well only for those patients who present with one or two metastatic nodules whereas for patients with 3 or more pulmonary metastases the prognosis is very poor; b) within the 4-drug regimen used in this study, the increment of ifosfamide dose from 10 g/m2 to 15 g/m2 for cycle does not improve prognosis; c) the strong correlation found between the histologic response of the primary tumor and metastases supports the strategy, largely used nowadays in the neoadjuvant treatment of osteosarcoma, of tailoring postoperative chemo-therapy on the basis of the primary tumor histologic response to preoperative chemotherapy.
我们报告了1995年至1997年间在里佐利骨科研究所接受治疗的28例患者的临床病程及结果,这些患者初诊时为肢体骨肉瘤伴肺转移。这些患者的治疗方案如下:采用顺铂、阿霉素及大剂量甲氨蝶呤和异环磷酰胺进行初始化疗,随后在可行的情况下同时切除原发灶和转移灶,并进一步化疗。初始化疗后,6例患者的肺转移灶消失,而3例患者的转移灶仍无法手术切除。这9例患者仅接受了原发肿瘤的手术治疗。在其余19例患者中,化疗后同时切除了原发肿瘤和转移瘤。18例患者的转移灶切除完全,1例不完全。4例未达到无瘤状态的患者中有3例在数月内死亡,1例仍存活但疾病未得到控制。在24例达到缓解的患者中,中位随访时间为32个月(19 - 43个月),12例(55%)持续无病生存,11例出现新的转移灶复发,1例死于化疗相关毒性。2年无病生存率(DFS)和总生存率(OS)分别为36%和53%。这些结果比同期治疗的114例局限性疾病的当代患者(2年DFS:81%)差得多,并且与之前采用相同方案但异环磷酰胺为标准剂量治疗的23例患者的结果(2年DFS:32%)相近。然而,必须强调的是,就预后而言,初诊时伴有转移疾病的患者是一个异质性群体。仅有1个或2个转移灶的患者DFS显著高于有3个或更多转移灶的患者(2年DFS:78%对28%)。在19例同时完全切除原发肿瘤和转移瘤的患者中,有12例发现原发灶和转移灶的坏死程度之间存在强相关性。我们得出结论,对于初诊时肢体骨肉瘤伴肺转移的患者:a)积极化疗联合同时切除原发肿瘤和转移瘤仅对那些有1个或2个转移结节的患者效果良好,而对于有3个或更多肺转移灶的患者预后很差;b)在本研究使用的四联方案中,每个周期异环磷酰胺剂量从10 g/m²增加到15 g/m²并不能改善预后;c)原发肿瘤和转移灶的组织学反应之间存在的强相关性支持了如今在骨肉瘤新辅助治疗中广泛采用的策略,即根据原发肿瘤对术前化疗的组织学反应来调整术后化疗。